Cure51 develops a clinical and molecular database that analyzes the biological features of long-term cancer survivors to identify novel therapeutic targets for drug development. By leveraging multi-omics data from biopsies, blood tests, and imaging, the company aims to enhance precision medicine and improve treatment outcomes for patients with lethal cancers.
Funding
$16.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug development for lethal cancers is hindered by a limited understanding of the biological factors that contribute to exceptional treatment responses and long-term survival in some patients. Identifying novel therapeutic targets requires comprehensive analysis of the molecular characteristics of these "outlier" cancer survivors.
Solution
Cure51 is developing a clinical and multi-omics database of long-term cancer survivors to identify novel therapeutic targets and advance precision medicine. The company collects and analyzes data from patients who have demonstrated exceptional responses to cancer therapies, focusing on those who have survived some of the most lethal cancers. By leveraging multi-omics data, Cure51's proprietary Discovery Platform aims to uncover multimodal signatures and create a library of robust targets that can contribute to the design of best-in-class drugs. The platform organizes and analyzes clinical and molecular data to discover actionable insights for novel therapeutics.
Target Audience
The primary audience includes oncology centers, researchers, and pharmaceutical companies focused on drug development and precision medicine for lethal cancers.
Features
- Clinical and multi-omics database of cancer survivors across various continents
- Focus on patients who have survived some of the most lethal cancers, such as Glioblastoma, Extensive Stage Small Cell Lung Cancer, and Metastatic Pancreatic Ductal Adenocarcinoma
- Proprietary Discovery Platform to organize, analyze, and discover novel therapeutic targets
- Computational biology team working with scientific partners to discover multimodal signatures
- Development of precision medicine tools to deliver actionable insights for novel therapeutics
- HDS labelised and ISO 27001 certified